Difference between revisions of "DZI19-121-Case-10"

From MGH Learn Pathology
(Automatic edit to upgrade to new templates)
Line 1: Line 1:
{{dziSlide
+
{{ServiceRequestCase
|order_date=September 11, 2019 01:58:41 PM
+
|identifier=DZI19-121-Case-10
|user=Em99
+
|intent=order
|slide_stain=H&E
+
|category=409073007
|slide_anatomy=Show
+
|priority=routine
}}
+
|orderDetail=case
{{dziCase
+
|locationCode=learn
|qc=yes
+
|basedOn=DZI19-121
|qcuser=Em99
+
|code=faculty
|qctime=Sep 13, 2019 20:41:00
+
|supportingInfo=Integrated diagnosis:  
|order_date=September 11, 2019 01:58:41 PM
 
|user=Em99
 
|dziorder=DZI19-121
 
|case_id=10
 
|clinical_hx=(ASCP CASE 9) 35 year old woman presents with new onset of tonic-clonic seizures
 
|case_diagnosis=Integrated diagnosis:  
 
 
PLEOMOPHIC XANTHOASTROCYTOMA, BRAF V600E MUTANT
 
PLEOMOPHIC XANTHOASTROCYTOMA, BRAF V600E MUTANT
  
Line 26: Line 20:
 
P53: weak in rare tumor cells (immunohistochemistry, consistent with wildtype)
 
P53: weak in rare tumor cells (immunohistochemistry, consistent with wildtype)
 
ATRX: nuclear expression retained (immunohistochemistry, consistent with wildtype)
 
ATRX: nuclear expression retained (immunohistochemistry, consistent with wildtype)
 +
|reasonCode=(ASCP CASE 9) 35 year old woman presents with new onset of tonic-clonic seizures
 +
|subject=public
 +
|performer=Mml55
 +
|authoredOn=September 11, 2019 01:58:41 PM
 +
|requester=Em99
 +
|sequence=10
 +
}}
 +
{{Media
 +
|basedOn=DZI19-121-Case-10
 +
|type=image
 +
|view=show
 +
|partOf=DZI19-121
 +
|frames=1
 +
|reasonCode=H&E
 +
|identifier=DZI19-121-Case-10_1
 +
|createdDateTime=September 11, 2019 01:58:41 PM
 +
|operator=Em99
 +
|modality=ndpi
 
}}
 
}}

Revision as of 13:39, March 9, 2022

DZI19-121-Case-10
(ASCP CASE 9) 35 year old woman presents with new onset of tonic-clonic seizures
Integrated diagnosis:

PLEOMOPHIC XANTHOASTROCYTOMA, BRAF V600E MUTANT

Histological diagnosis: Pleomorphic xanthoastrocytoma

WHO histological grade: II

Molecular information: BRAF V600E: MUTANT (sequencing) IDH: wildtype (IDH1/2 sequencing) P53: weak in rare tumor cells (immunohistochemistry, consistent with wildtype)

ATRX: nuclear expression retained (immunohistochemistry, consistent with wildtype)
December 31, 1969 7:00:00 PM